A recent update of the American Society of Clinical Oncology (ASCO) guidelines strongly recommended the use of Oncotype Dx® in pre- and postmenopausal (>50 yrs) women with early stage, ER + /HER2- node-negative BC to guide decision on adjuvant CHT. The gene discussed is ESR1; the disease is breast cancer.